香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ASCENTAGE PHARMA GROUP INTERNATIONAL 亞盛醫藥集團 （在開曼群島註冊成立的有限公司） （股份代號：6855） 截至2025年6月30日止六個月未經審核中期業績公告 董事會欣然宣佈亞盛醫藥集團截至2025年6月30日止六個月的未經審核綜合業 績，連同截至2024年6月30日止六個月的比較數字。 財務摘要 截至2025年6月30日止六個月，收益為人民幣233.7百萬元（32.6百萬美元）， 較截至2024年6月30日止六個月減少人民幣590.0百萬元（80.7百萬美元）或 71.6%，主要是由於截至2024年6月30日止六個月產生的人民幣678.4百萬元 （95.3百萬美元）的知識產權收益導致。耐立克® （奧雷巴替尼）在中國的產品銷售 較截至2024年6月30日止六個月的人民幣112.9百萬元（15.5百萬美元），增加人 民幣104.5百萬元（14.9百萬美元）或93%至 ...

Core Viewpoint - As of August 18, 2023, AAPG's stock price increased by 5.35%, reaching $47.4 per share, with a total market capitalization of $4.406 billion. The company reported a total revenue of 981 million RMB for the year ending December 31, 2024, representing a year-on-year growth of 341.77%, while the net profit attributable to shareholders was -405 million RMB, showing a year-on-year increase of 56.2% [1]. Financial Performance - AAPG's total revenue for the fiscal year ending December 31, 2024, is projected to be 981 million RMB, reflecting a significant year-on-year growth of 341.77% [1]. - The net profit attributable to shareholders is expected to be -405 million RMB, which indicates a year-on-year increase of 56.2% [1]. Upcoming Events - AAPG is scheduled to disclose its mid-year report for the fiscal year 2025 on August 20, 2023, after the market closes (Eastern Time) [2]. Company Overview - AAPG is a biopharmaceutical company based in China, focusing on developing innovative drugs for cancer, hepatitis B, and age-related diseases. The company was listed on the Hong Kong Stock Exchange on October 28, 2019, under the stock code 6855.HK [3]. - AAPG has established a proprietary drug design platform targeting protein-protein interactions and is at the forefront of developing new drugs in the apoptosis pathway. The company has a pipeline of nine clinical-stage Class 1 small molecule drugs, including inhibitors targeting key proteins in the apoptosis pathway [3]. - The core product, Olarebatin (brand name: Nairike), has been approved in China and is included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2022). It has also received various designations from the FDA and the EU [3]. - AAPG has engaged in over 40 clinical trials across China, the U.S., Australia, and Europe, and has established collaborations with leading biotech and pharmaceutical companies and academic institutions globally [3].

Major Events - Double End Co., Ltd. plans to globally offer 58.557 million H-shares from August 18 to August 21, with San Shui Venture Capital as a cornerstone investor [1] - Sunac China intends to issue mandatory convertible bonds and adopt a team stability plan [1] - Ascentage Pharma-B received FDA and EMA approval for the global registration of its Phase III clinical trial for the treatment of high-risk MDS patients [1] - 361 Degrees' subsidiary entered into a strategic cooperation agreement with Stand [1] - Eagle Precision indicates that additional tariffs may impact its business and operations [1] - Green Leaf Pharmaceutical's clinical trial for the treatment of generalized anxiety disorder has completed patient enrollment in China [1] - Tian Tu Investment and HashKey Capital signed a strategic cooperation memorandum to establish a virtual asset investment fund [1] - China Rare Earth Holdings expects annual gold production from MtBundy and Cygnet gold projects to exceed 200,000 ounces [1] Operating Performance - Xinhua Insurance reported a cumulative original insurance premium income of 137.806 billion yuan in the first seven months, a year-on-year increase of 23% [1] - China Biologic Products announced mid-term revenue of 17.57 billion yuan, up 10.7% year-on-year [1] - Meitu Inc. reported a mid-term profit attributable to shareholders of 397 million yuan, a year-on-year increase of 30.84%, with strong growth in MAU and paid subscribers [1] - Xtep International reported a mid-term profit attributable to shareholders of 914 million yuan, a year-on-year increase of 21.47% [1] - Leap Motor achieved a net profit of 33.03 million yuan in the first half of the year, marking its first positive half-year net profit [1] - Hansoh Pharmaceutical reported a mid-term profit attributable to shareholders of 3.135 billion yuan, a year-on-year increase of 15.02% [1] - Kangzheng Pharmaceutical announced a mid-term profit attributable to shareholders of approximately 941 million yuan, a year-on-year growth of 3.38% [1] - Kelun-Bio reported mid-term revenue of 950 million yuan with R&D expenses of 612 million yuan [1] - Sinopec Oilfield Services reported a net profit of approximately 492 million yuan in the first half, a year-on-year increase of 9% [1] - Wanwu Cloud reported a mid-term profit attributable to shareholders of 792 million yuan, a year-on-year increase of 3.88% [1] - Yunfeng Financial expects a significant year-on-year increase of approximately 139% in net profit attributable to equity shareholders, estimated at around 480 million HKD for the first half [1] - United Pharmaceutical anticipates a mid-term net profit of approximately 1.85 billion yuan, a year-on-year increase [1] - Sipai Health reported a mid-term overall gross margin increase of 4.7 percentage points to 14.4% [1] - Orange Sky Golden Harvest expects a net profit attributable to shareholders of no less than 125 million HKD for the first half, marking a turnaround from loss to profit [1] - Baifu Global reported a mid-term profit attributable to shareholders of 391 million HKD, proposing an interim dividend of 0.25 HKD per share [1] - WuXi AppTec reported a mid-term profit attributable to shareholders of 746 million yuan, a year-on-year increase of 52.74% [1] - Joy City Property reported a total contract sales amount of approximately 2.749 billion yuan in the first half, a year-on-year decrease of 81.4% [1]

Market Overview - The Hong Kong stock market experienced a pullback after an initial rise, with the Hang Seng Index closing down 0.37% at 25,176.85 points and a total turnover of HKD 312.78 billion [1] - The market is currently in a phase of volatility with a lack of clear trading themes, as significant domestic and international events are awaited [1] Blue-Chip Stocks Performance - JD Health (06618) led the blue-chip stocks with an increase of 8.41%, closing at HKD 66.4, contributing 9.14 points to the Hang Seng Index [2] - Other notable performers included Alibaba Health (00241) up 3.56% and ZTO Express (02057) up 3.14%, while Kang Shifu Holdings (00322) and China Shenhua (01088) saw declines of 3.23% and 2.65% respectively [2] Sector Highlights - The film and entertainment sector showed strong performance, with companies like Lingmeng Film (09857) and Yuewen Group (00772) rising 21.33% and 15.34% respectively [3][4] - The brokerage sector continued its upward trend, with notable gains from CITIC Securities (06030) and Guotai Junan (01456) [4] Pharmaceutical Sector - The pharmaceutical sector saw a resurgence, with companies like Zhonghui Biopharma (02627) and Junshi Biosciences (01877) increasing by 13.4% and 13.25% respectively [5] - Upcoming academic conferences such as WCLC and ESMO are expected to catalyze interest in Chinese innovative drugs, with several companies set to present significant clinical trial results [6] Notable Stock Movements - Yasheng Life Services (03319) reported a profit warning, leading to a 13.06% increase in its stock price [7] - Great Wall Motors (02333) saw a strong performance with a 10.21% rise following the pre-sale of its new model [8] - Xtep International (01368) and ZTE Corporation (00763) also experienced significant gains of 7.33% and 7.22% respectively [9][10] - Conversely, Hua Hong Semiconductor (01347) faced a decline of 6.2% due to news of a planned acquisition [11] and Standard Chartered Group (02888) dropped 5.29% amid allegations of illegal payments [12]

Core Viewpoint - Ascentage Pharma-B (06855) saw a significant increase in stock price, opening over 4% higher and reaching a historical high of 90 HKD, with a trading volume of 16.89 million HKD, following the announcement of a global Phase III clinical trial approval for its drug, APG-2575 [1] Group 1: Clinical Development - The company announced that its self-developed Bcl-2 selective inhibitor, APG-2575 (trade name: Lisatuzumab), has received approval from both the FDA and EMA to initiate a global Phase III clinical study (GLORA-4) for treating newly diagnosed high-risk myelodysplastic syndromes (HR-MDS) patients in combination with Azacitidine [1] - GLORA-4 is the second global Phase III study for Lisatuzumab approved by regulatory agencies in Europe and the U.S., which will expedite the drug's market entry [1] - Lisatuzumab is a novel oral Bcl-2 selective inhibitor that selectively inhibits the Bcl-2 protein, restoring the normal apoptosis process in cancer cells to achieve tumor treatment [1] Group 2: Market Position - The product has already been approved for marketing in China for adult chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients who have previously undergone at least one systemic treatment, including a Bruton tyrosine kinase (BTK) inhibitor [1] - Lisatuzumab is the first domestically developed original Bcl-2 inhibitor approved for marketing in China and is currently the only Bcl-2 inhibitor advancing to a Phase III clinical trial for high-risk MDS internationally [1]

Market Overview - The Shanghai Composite Index reached a new high of 3731.76 points, surpassing the previous peak of 3731.69 points from February 18, 2021, marking the highest level since August 19, 2015 [2][3] - A-shares saw a total trading volume exceeding 1.6 trillion yuan, with 4188 stocks rising [2] - The ChiNext Index increased by over 3% [2] Hong Kong Market Performance - The three major indices in Hong Kong opened higher, with the Hang Seng Index up by 0.09%, the Hang Seng China Enterprises Index up by 0.21%, and the Hang Seng Tech Index rising by 0.4% [3] - The Hang Seng Tech Index further increased by 1.45% to 5623.32 points [3] Sector Performance - The innovative pharmaceutical sector in Hong Kong showed strong performance, with stocks like Ascentage Pharma rising over 10% and others like Sihuan Pharmaceutical and XinTai Medical increasing by over 8% [5] - The consumer electronics sector experienced a short-term rally, leading gains in communication equipment, computer hardware, software, internet, and electronic components [7] - Notable stocks included Yidong Electronics, which rose over 18%, and Nanya New Materials, which increased over 17% [8] Noteworthy Stocks and Trends - HaiNeng Technology and JingSai Technology hit their daily limit up [9] - The brokerage sector continued to rise, with Changcheng Securities recording four consecutive trading limits, and other firms like Western Securities and Dazhihui increasing by over 5% [9] - The tourism sector also saw gains, with stocks like Tibet Tourism and Caesar Travel hitting their daily limit up [9]

Core Insights - The approval of the second global Phase III clinical trial for the drug Lisatoclax (brand name: Lishengtuo®) has led to a significant increase in the stock price of Ascentage Pharma-B (06855), reaching a new high of 95.35 HKD on August 18, with a year-to-date increase of 100.88% [1][2] Company Developments - Ascentage Pharma announced that the global Phase III clinical study (GLORA-4) for Lisatoclax in combination with Azacitidine (AZA) for newly diagnosed high-risk myelodysplastic syndromes (HR-MDS) patients has received approval from the FDA and EMA [1][2] - The GLORA-4 study is a multi-center, randomized, double-blind trial aimed at evaluating the efficacy and safety of Lisatoclax combined with AZA compared to placebo plus AZA in adult HR-MDS patients [2][3] - The study has already commenced patient enrollment globally, with the first patients enrolled in China and Europe [2] Market Context - MDS is characterized by a significant age-related incidence, with a yearly incidence rate of 22 per 100,000 in individuals over 65 years old, and a median diagnosis age of 70 years [2] - The transformation rate to acute myeloid leukemia (AML) in high-risk MDS patients is alarmingly high, with a 5-year transformation rate of 40-60% [2][3] Product Efficacy - Lisatoclax is a novel oral Bcl-2 selective inhibitor that restores normal apoptosis in cancer cells, showing promising clinical benefits in previous studies [3][4] - In preliminary studies presented at major conferences, Lisatoclax combined with AZA achieved an overall response rate (ORR) of 75% in treatment-naive MDS patients, significantly higher than existing therapies [4][5] Future Prospects - The successful execution of the GLORA-4 study is expected to accelerate the clinical development and registration process for Lisatoclax in MDS indications [6] - The company aims to address unmet clinical needs globally, with hopes that Lisatoclax will become the first approved targeted therapy for first-line treatment of high-risk MDS patients [5][6]

Core Viewpoint - The recent approval of the second global Phase III clinical trial for the drug Lisatoclax (brand name: Lishengtuo®) has led to a significant increase in the stock price of Ascentage Pharma-B (06855), reaching a new high of 95.35 HKD, with a year-to-date increase of 100.88% [1][2]. Group 1: Clinical Development - The GLORA-4 study, which is a global Phase III clinical trial for Lisatoclax in combination with Azacitidine (AZA) for newly diagnosed high-risk myelodysplastic syndromes (HR-MDS) patients, has received approval from the FDA and EMA [1][2]. - This study is notable as it is the only ongoing Phase III clinical trial for a Bcl-2 inhibitor in the high-risk MDS category, aiming to address a significant clinical gap in this area [2]. - The trial is designed as an international, multi-center, randomized, double-blind study to evaluate the efficacy and safety of Lisatoclax combined with AZA compared to placebo plus AZA in adult HR-MDS patients [2]. Group 2: Disease Context - Myelodysplastic syndromes (MDS) are characterized by a significant age-related incidence, with a rate of 22 per 100,000 in individuals over 65 years old, and a median diagnosis age of 70 years [3]. - The transformation rate to acute myeloid leukemia (AML) in high-risk MDS patients is alarmingly high, with a 5-year transformation rate of 40-60%, leading to poor prognosis [3]. - Current first-line treatments for high-risk MDS, such as demethylating agents, show limited efficacy, with overall response rates of only 30-40% and complete response rates of 10-17% [3]. Group 3: Drug Profile - Lisatoclax is a novel oral Bcl-2 selective inhibitor developed by Ascentage Pharma, designed to restore normal apoptosis in cancer cells [4]. - The drug has already been approved in China for use in adult chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients who have undergone prior systemic therapy [4]. - Preliminary data from the 2024 American Society of Hematology (ASH) and 2025 American Society of Clinical Oncology (ASCO) meetings indicate that Lisatoclax combined with AZA achieves an overall response rate of 75% in treatment-naive MDS, significantly outperforming existing therapies [4]. Group 4: Market Potential - The approval of the GLORA-4 study is expected to accelerate the clinical development and registration process for Lisatoclax in MDS indications, addressing a substantial unmet clinical need in the market [5][6]. - The company aims to position Lisatoclax as the first targeted therapy approved for first-line treatment of high-risk MDS patients, potentially reshaping the treatment landscape in this area [5][6].

Group 1: Hong Kong Stocks - Ascentage Pharma-B (06855) opened over 5% higher after receiving FDA and EMA approval for its drug, Lisenglitazone, for high-risk MDS in Phase III clinical trials [1] - Haijia Medical (06078) fell over 5% following a profit warning, expecting a mid-term net profit decline of approximately 34% to 39% due to factors like centralized procurement and increased depreciation from new hospitals [1] - Hua Hong Semiconductor (01347) dropped over 6% as it announced plans to acquire a controlling stake in Shanghai Huali Microelectronics to address industry competition [1] - Zhonghui Biotech-B (02627) rose over 8% after receiving IND approval for its recombinant respiratory syncytial virus vaccine in both the US and China [1] - NetDragon (00777) surged over 10% after forming a strategic alliance with Zhongke Wenge to promote AI technologies abroad [1] - Great Wall Motors (02333) increased over 12% following the completion of its factory in Brazil, with an initial production capacity of 30,000 vehicles per year [1] - Yuewen Group (00772) rose over 20% as its first-half performance exceeded expectations, benefiting from growth in licensing business and steady performance of short dramas [1] Group 2: Other Notable Stocks - Huirui Group (00806) increased over 8% after reporting first-half results that met market expectations and is applying for MRF mutual recognition for other products [2] - Soundon Technology (02495) surged nearly 30% after announcing a projected net profit exceeding 50 million yuan for the first half, marking a turnaround from losses [2] - Robotics concept stocks saw significant gains, with Jinshang Machine Tool (01651) up over 11% and Lijin Technology (00558) up over 3% [2] Group 3: US Stocks - Intel (INTC.US) rose 2.93% amid reports of negotiations with the Trump administration for government investment to support domestic manufacturing [3] - Hesai Technology (HSAI.US) increased 9.73% after reporting over 50% year-on-year revenue growth for Q2 2025 [3] - UnitedHealth (UNH.US) surged 11.98% following Berkshire Hathaway's new investments in the company [3] - NIO (NIO.N) rose 8.09% as it announced the upcoming launch of its new ES8 model [4] - Xunlei (XNET.US) continued to rise by 26.53% after reporting a 30.6% year-on-year revenue increase for Q2 2025 [5]

Market Performance - The ChiNext Index surged nearly 2%, reaching 2581.45 points, marking a new high since the "9·24" market rally last year [2] - The Shenzhen Component Index increased by over 1%, while the North Stock 50 Index rose over 2%, surpassing the 1500-point mark for the first time [2] - In the Hong Kong market, the Hang Seng Technology Index rose by 1.45% to 5623.32 points [4] Sector Performance - The consumption electronics sector experienced a short-term rally, with industries such as communication equipment, computer hardware, software, internet, and electronic components leading the market [6] - Innovative drug stocks in Hong Kong showed strong performance, with companies like Ascentage Pharma rising over 10% [5] Notable Stocks - Yidong Electronics surged over 18%, while Nanya New Materials increased by over 17% [7] - The stock of Ying Shi Innovation hit the daily limit up for two consecutive days, reaching a historical high with a total market value of 108 billion [7] - Eastern Fortune reported a 37% year-on-year increase in net profit for the first half of the year, with brokerage business stock trading volume reaching 16.03 trillion yuan [9] Market Trends - The semiconductor sector is under scrutiny due to potential new tariffs announced by Trump, which could increase the tax rate significantly [8] - The tourism sector saw a rise, with companies like Tibet Tourism and Caesar Travel hitting the daily limit up [9]